BioCryst to stop testing galidesivir in COVID-19 patients

 

• BioCryst (NASDAQ:BCRX) drops 8% in premarket, after announcing part 1 data from NIAID-funded Phase 1 trial evaluating galidesivir (BCX4430), broad-spectrum antiviral, in COVID-19 patients.
• The company said that the trial initiated in April this year was not designed or sized to demonstrate clinical efficacy and no clinical efficacy benefit with galidesivir treatment compared to placebo treatment was observed.
• Based on ongoing discussions with the National Institute of Allergy and Infectious Diseases (NIAID), the company expects NIAID to continue their support for the development of galidesivir with a focus on biodefense threats, such as Marburg virus disease, and to discontinue the pursuit of a COVID-19 indication for galidesivir.
• BioCryst is engaged in ongoing discussions with NIAID to define specific further galidesivir studies that NIAID would support.
• https://seekingalpha.com/news/3646567-biocryst-to-stop-testing-galidesivir-in-covidminus-19-patients